Literature DB >> 16775295

Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage.

L Hacein-Bey1, D R Harder, H T Meier, P N Varelas, N Miyata, K K Lauer, J F Cusick, R J Roman.   

Abstract

PURPOSE: Arachidonic acid is avidly metabolized to a potent vasoconstrictor, 20-hydroxyeicosatetraenoic acid (20-HETE), in the cerebral circulation. 20-HETE has been reported to contribute to the acute fall in cerebral blood flow following subarachnoid hemorrhage (SAH), but its role in the development of delayed vasospasm is unknown. The present study examined whether delayed vasospasm is associated with elevations in 20-HETE in CSF in the dual hemorrhage model of SAH in dogs and if blockade of the synthesis of 20-HETE with N-(3-chloro-4-morpholin-4-yl)phenyl-N'-hydroxyimido formamide (TS-011) can reverse delayed vasospasm in this model.
MATERIALS AND METHODS: Delayed vasospasm was induced in 22 adult beagle dogs by dual injection of blood (0.5 mL/kg) into the cisterna magna on days 1 and 4. Sequential samples of CSF were collected before intracisternal injections of blood on days 1 and 4 and after the development of delayed vasospasm on day 7. Sequential angiograms were obtained before and after intracisternal injection of blood on days 1 and 4 and before and 1 hour after administration of TS-011 (1 mg/kg IV) on day 7.
RESULTS: The dogs consistently developed delayed vasospasm, and the diameter of the basilar artery fell to 68 +/- 3% (n = 15), 3 days after the second intracisternal injection of blood. The levels of 20-HETE in CSF increased from 4 +/- 2 to 39 +/- 16 pg/mL. In 9 dogs with delayed vasospasm, acute blockade of the synthesis of 20-HETE with TS011 (1 mg/kg IV) significantly increased the diameter of the basilar artery by 39%. Chronic administration of TS-011 (1 mg/kg per day) attenuated the development of delayed vasospasm, and the diameter of the basilar artery fell by 17 +/- 1% versus the 33 +/- 3% decrease in diameter seen in control animals 3 days following the second injection of blood into the cisterna magna.
CONCLUSIONS: These results indicate that the development of delayed vasospasm in dogs is associated with an increase in 20-HETE levels in CSF, and acute blockade of the synthesis of 20-HETE with TS-011 reverses delayed vasospasm in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775295      PMCID: PMC8133904     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  29 in total

Review 1.  Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue.

Authors:  D R Harder; A R Lange; D Gebremedhin; E K Birks; R J Roman
Journal:  J Vasc Res       Date:  1997 May-Jun       Impact factor: 1.934

Review 2.  Regulation of the cerebral circulation: role of endothelium and potassium channels.

Authors:  F M Faraci; D D Heistad
Journal:  Physiol Rev       Date:  1998-01       Impact factor: 37.312

3.  Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage.

Authors:  Liana Cambj-Sapunar; Ming Yu; David R Harder; Richard J Roman
Journal:  Stroke       Date:  2003-04-03       Impact factor: 7.914

4.  Production of 20-HETE and its role in autoregulation of cerebral blood flow.

Authors:  D Gebremedhin; A R Lange; T F Lowry; M R Taheri; E K Birks; A G Hudetz; J Narayanan; J R Falck; H Okamoto; R J Roman; K Nithipatikom; W B Campbell; D R Harder
Journal:  Circ Res       Date:  2000-07-07       Impact factor: 17.367

5.  Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II.

Authors:  A Oyekan; M Balazy; J C McGiff
Journal:  Am J Physiol       Date:  1997-07

6.  Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current.

Authors:  D Gebremedhin; A R Lange; J Narayanan; M R Aebly; E R Jacobs; D R Harder
Journal:  J Physiol       Date:  1998-03-15       Impact factor: 5.182

Review 7.  Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions for therapy.

Authors:  C G Sobey
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-11       Impact factor: 2.557

8.  Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels.

Authors:  D R Harder; D Gebremedhin; J Narayanan; C Jefcoat; J R Falck; W B Campbell; R Roman
Journal:  Am J Physiol       Date:  1994-05

9.  Experimental subarachnoid hemorrhage: subarachnoid blood volume, mortality rate, neuronal death, cerebral blood flow, and perfusion pressure in three different rat models.

Authors:  Giselle Fabiana Prunell; Tiit Mathiesen; Nils Henrik Diemer; Niels-Aage Svendgaard
Journal:  Neurosurgery       Date:  2003-01       Impact factor: 4.654

10.  Subarachnoid haemorrhage in the rat: angiography and fluorescence microscopy of the major cerebral arteries.

Authors:  T J Delgado; J Brismar; N A Svendgaard
Journal:  Stroke       Date:  1985 Jul-Aug       Impact factor: 7.914

View more
  18 in total

1.  Additive Neuroprotection of a 20-HETE Inhibitor with Delayed Therapeutic Hypothermia after Hypoxia-Ischemia in Neonatal Piglets.

Authors:  Junchao Zhu; Bing Wang; Jeong-Hoo Lee; Jillian S Armstrong; Ewa Kulikowicz; Utpal S Bhalala; Lee J Martin; Raymond C Koehler; Zeng-Jin Yang
Journal:  Dev Neurosci       Date:  2015-02-25       Impact factor: 2.984

2.  Impaired vascular responses of insulin-resistant rats after mild subarachnoid hemorrhage.

Authors:  Adam Institoris; James A Snipes; Prasad V Katakam; Ferenc Domoki; Krisztina Boda; Ferenc Bari; David W Busija
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

Review 3.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

Review 4.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

5.  Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage.

Authors:  Elizabeth A Crago; Bhavani P Thampatty; Paula R Sherwood; Chie-Wen J Kuo; Catherine Bender; Jeffrey Balzer; Michael Horowitz; Samuel M Poloyac
Journal:  Stroke       Date:  2011-05-26       Impact factor: 7.914

6.  Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats.

Authors:  Kathryn M Dunn; Marija Renic; Averia K Flasch; David R Harder; John Falck; Richard J Roman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-24       Impact factor: 4.733

Review 7.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

Review 8.  Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.

Authors:  Hui Huang; Mohamed Al-Shabrawey; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-12-30       Impact factor: 3.072

9.  Rapid, simultaneous quantitation of mono and dioxygenated metabolites of arachidonic acid in human CSF and rat brain.

Authors:  Tricia M Miller; Mark K Donnelly; Elizabeth A Crago; Dana M Roman; Paula R Sherwood; Michael B Horowitz; Samuel M Poloyac
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-10-14       Impact factor: 3.205

10.  Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion.

Authors:  Marija Renic; Judith A Klaus; Tomohiro Omura; Naoya Kawashima; Michihito Onishi; Noriyuki Miyata; Raymond C Koehler; David R Harder; Richard J Roman
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-24       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.